预约演示
更新于：2026-10-23
Lamotrigine
拉莫三嗪
更新于：2026-10-23
概要
基本信息
简介拉莫三嗪是一种抗惊厥药物，于1994年12月27日首次被美国食品和药品管理局批准上市。由制药公司葛兰素史克开发的，主要用于治疗Lennox Gastaut综合征、癫痫和双相情感障碍等疾病。拉莫三嗪的作用机制是通过阻断大脑中的钠通道，以稳定神经元的电活动，减轻癫痫发作的严重程度和频率。此外，拉莫三嗪还被用于治疗双相情感障碍的抑郁症状。该药物已被证明对减少癫痫发作的频率和改善患者生活质量具有显著疗效。 |
药物类型 小分子化药 |
别名 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine、Lamotrigine (JAN/USP/INN)、430-C-78 + [15] |
作用方式 阻滞剂 |
作用机制 钠通道阻滞剂 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 (1990-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C9H7Cl2N5 |
InChIKeyPYZRQGJRPPTADH-UHFFFAOYSA-N |
CAS号84057-84-1 |
关联
239
项与 拉莫三嗪 相关的临床试验ChiCTR2600121573
Exploration and mechanism research on the preventive and synergistic therapeutic effects of systematic interpersonal therapy on depressive disorders with mixed characteristics in adolescents
NCT06929273
A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania With Mixed Features in Bipolar-I Disorder (BALSAM-3)
CTR20252056
拉莫三嗪分散片的生物等效性试验（空腹用药试验）
100 项与 拉莫三嗪 相关的临床结果
登录后查看更多信息
100 项与 拉莫三嗪 相关的转化医学
登录后查看更多信息
100 项与 拉莫三嗪 相关的专利（医药）
登录后查看更多信息
8,724
项与 拉莫三嗪 相关的文献（医药）2027-01-01CLINICAL NEUROLOGY AND NEUROSURGERY
Time-dependent retention and discontinuation of eslicarbazepine acetate treatment in real-world focal epilepsy: The first three months as a key period
Article
作者: Park, Jiyun ; Winter, Yaroslav ; Koo, Yong Seo
PURPOSE:
Eslicarbazepine acetate (ESL) is a widely used anti-seizure medication (ASM), used as monotherapy or adjunctive therapy for patients with focal epilepsy, including drug-resistant epilepsy. Detailed analyses of factors associated with treatment outcomes are limited; therefore, this study evaluated 12-month retention, responder, and seizure freedom rates, focusing on time-specific associated baseline characteristics.
METHODS:
This single-centre, retrospective, observational study included patients (≥19 years) with focal epilepsy who initiated ESL treatment from November 2022 to December 2024. Treatment efficacy was evaluated by retention, responder (≥50% seizure reduction compared with baseline) and seizure freedom rate at 3, 6, and 12 months. Tolerability was assessed based on adverse events reported by patients.
RESULTS:
In 12-month analysis cohort (n = 180; mean age 48.5 ± 15.9 years; 50.6% men), the retention rate was 69.4%. Of 210 patients initiating ESL, 85 (40.5%) had non-retention or unavailable follow-up; 62 cases (72.9%) occurred within first 3 months. Adverse events were most common. A higher retention rate was associated with epileptiform discharge on electroencephalogram, whereas a lower retention rate was associated with baseline seizure frequency. Most reported adverse events occurred within 3 months of ESL initiation (74.4%). More adverse events were associated with concomitant ASM use, particularly lacosamide and lamotrigine. The five most common adverse events were constant at 3, 6, and 12 months.
CONCLUSION:
The first 3 months are a key period for optimizing treatment retention and minimizing adverse events. Careful consideration of concomitant ASM is required, as concomitant ASM may be associated with lower retention and more adverse events, particularly sodium channel blockers.
2027-01-01JOURNAL OF AFFECTIVE DISORDERS
Augmentation strategies for intravenous ketamine in treatment-resistant depression: A systematic review and meta-analysis
Review
作者: Al-Shamali, Huda F ; Jetly, Rakesh ; Janssen-Aguilar, Reinhard ; Greenshaw, Andrew ; Tanguay, Robert ; Taylor, Kaija ; Dunn, Walter ; Joseph, Jithin ; Bhat, Venkat ; Jha, Manish ; Zhao, Zixu ; Lin, Qiaowei ; Zhang, Yanbo ; Swainson, Jennifer ; Lou, Wendy
Treatment-resistant depression (TRD) affects 30-60% of individuals with major depressive disorder and carries substantial morbidity and healthcare costs. Intravenous (IV) ketamine (KET) is a rapid-acting antidepressant, but benefits are often transient, prompting augmentation to sustain efficacy or improve tolerability. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) of IV KET augmentation in adults with TRD. MEDLINE, Embase, and PsycINFO were searched through October 29, 2025. Eligible studies compared KET plus augmentation with KET plus placebo/sham or active control. Seven RCTs (N = 346) met inclusion criteria. Strategies included glutathione, riluzole, lamotrigine, lithium, D-cycloserine and ketamine combined with psychotherapy (KCP) approaches involving cognitive behavioral therapy (CBT) and automated self-association training (ASAT). Across the included trials, IV KET was associated with antidepressant improvement, although augmentation strategies generally did not demonstrate additional benefit over their respective control conditions. Pharmacological augmentation strategies did not demonstrate additional benefit at primary endpoints. KCP approaches using CBT and ASAT yielded preliminary signals of improved maintenance of antidepressant effects, although each was evaluated in a single study. An exploratory random-effects meta-analysis of seven heterogeneous comparisons found no statistically significant overall difference in depressive symptoms between augmentation and control conditions (SMD = -0.12; 95% CI, -0.37 to 0.12; p = 0.323; I2 = 0.0%). No clear new safety signal emerged in the trials, although adverse-event reporting was heterogeneous across studies. Overall, low-certainty randomized evidence is insufficient to support routine augmentation of IV ketamine for TRD, highlighting the need for larger, rigorously designed trials to determine whether specific strategies can meaningfully extend ketamine's antidepressant effects.
2026-12-01PSYCHIATRY RESEARCH
Therapeutic strategies after discontinuation of valproate in females of child-bearing potential with bipolar disorder: an insurance claims database study in France and the United Kingdom
Article
作者: Czekalla, Joerg ; Longin, Juliette ; Blin, Patrick ; Colas, Sandrine ; Carcaillon-Bentata, Laure ; Rouyer, Magali ; Bigat, David ; Etain, Bruno ; Bernard, Marie-Agnès ; Li, Xinyu ; Bignon, Emmanuelle ; Kaplan, Sigal
Valproate is contraindicated in pregnant women with bipolar disorder (BD) and must not be prescribed to females of child-bearing potential (FCBP) unless complying with the pregnancy prevention programme. This post-authorization safety study aimed to identify the treatment patterns within 1-year following valproate discontinuation in FCBP. The success in BD management after valproate discontinuation was defined as no valproate reintroduction in the follow-up period. FCBP with BD were identified between January 1, 2014, and December 31, 2017, from SNDS (France) and CPRD GOLD (UK) databases and followed up for 1 year. A total of 9,943 (SNDS) and 144 (CPRD) FCBP were included; 66.9% (SNDS) and 63.2% (CPRD) were part of clusters where alternative treatment was considered successful. After valproate discontinuation, 32.7% of FCBP tended to not use any BD-treatment, 25.6% and 8.6% used 1 and 2 BD-treatments, respectively in SNDS; and 22.2%, 14.6%, 10.4%, and 16% of FCBP tended to use 0, 1, 2, and mixed mood stabilizers, respectively, in CPRD. In SNDS, the factors most associated with success were prescription of lamotrigine or lithium within 90-days before index date, dose-tapering phase in 1-year before index date, pregnancy starting in the year before index date. The factors most strongly associated with valproate reintroduction were older age, longer history of BD, and no exposure to a BD-treatment within 3-months after index date. Valproate discontinuation was maintained in 47.9% (SNDS) and 51.4% (CPRD) of FCBP, especially in young women, with stable disease. Decisions on BD treatment in FCBP should consider both maternal mental health and fetal safety.
100 项与 拉莫三嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 失神发作 | 日本 | 2015-09-24 | |
| 全身性癫痫 | 日本 | 2008-10-16 | |
| 躁郁症1型 | 美国 | 2003-06-20 | |
| 癫痫部分性发作 | 美国 | 1998-08-24 | |
| 强直阵挛性癫痫 | 中国 | 1996-07-02 | |
| Lennox-Gastaut综合征 | 美国 | 1994-12-27 | |
| 癫痫发作 | 美国 | 1994-12-27 | |
| 躁郁症 | - | 1990-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 抑郁症 | 临床3期 | 中国 | 2012-08-21 | |
| 抑郁症 | 临床3期 | 中国 | 2012-08-21 | |
| 抑郁症 | 临床3期 | 中国 | 2012-08-21 | |
| 暴食症 | 临床3期 | 美国 | 2006-03-01 | |
| 肥胖 | 临床3期 | 美国 | 2006-03-01 | |
| 癫痫 | 临床3期 | 美国 | 2005-10-01 | |
| 糖尿病性神经病变 | 临床3期 | 丹麦 | 2005-04-06 | |
| 疱疹后神经痛 | 临床3期 | 美国 | 2005-02-01 | |
| 精神分裂症 | 临床3期 | 美国 | 2003-08-01 | |
| 躁狂 | 临床3期 | 荷兰 | 2002-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 226 | Lithium | 鏇艱簾鹽鏇鹽範積鬱衊(構網膚願蓋餘窪衊範窪) = 蓋鬱鹽積廠鏇構艱醖願 夢願觸憲觸膚簾鹽鏇廠 (窪夢壓憲糧餘簾廠艱範 ) 更多 | 积极 | 2026-05-01 | ||
鏇艱簾鹽鏇鹽範積鬱衊(構網膚願蓋餘窪衊範窪) = 蓋築餘醖積築鏇遞醖願 夢願觸憲觸膚簾鹽鏇廠 (窪夢壓憲糧餘簾廠艱範 ) 更多 | |||||||
临床4期 | 5 | 鬱簾醖襯顧衊鏇窪獵願(鬱築憲醖鹽製壓衊醖淵) = 獵醖餘構築糧遞齋蓋積 顧繭積鹹衊齋醖夢選淵 (醖積築襯餘積憲餘鹹艱 ) 更多 | 积极 | 2026-02-01 | |||
蓋繭夢鬱築鏇艱鹽構選(鹽廠齋鏇鬱襯餘壓遞淵) = 鹹蓋鑰蓋網廠膚廠簾餘 餘繭選簾憲艱衊醖獵糧 (繭構鬱壓顧製齋憲網膚 ) 更多 | |||||||
FDA_CDER 人工标引  | N/A | 575 | lamotrigine 50 mg/day (Trial 1) | 製醖願糧夢膚鏇膚顧窪(網鹹廠艱糧艱繭蓋範簾) = superior to placebo in delaying the time to occurrence of a mood episode 餘獵蓋壓鏇鹽淵廠願觸 (獵範襯鑰範範願願壓繭 ) | 积极 | 2025-09-16 | |
lamotrigine 200 mg/day (Trial 1) | |||||||
FDA_CDER 人工标引 | N/A | 117 | 鹹憲襯醖網積壓壓範淵(憲齋淵鬱夢廠鹹選選簾) = 繭壓餘鏇築獵築構齋淵 鹹醖顧製觸醖遞鹹夢廠 (夢構網襯製壓糧壓糧顧 ) | 积极 | 2025-09-16 | ||
Placebo | 鹹憲襯醖網積壓壓範淵(憲齋淵鬱夢廠鹹選選簾) = 鬱鑰鑰繭選廠襯獵齋鬱 鹹醖顧製觸醖遞鹹夢廠 (夢構網襯製壓糧壓糧顧 ) | ||||||
FDA_CDER 人工标引 | N/A | 199 | 憲壓壓獵餘製餘壓構蓋(夢鬱夢顧顧窪鑰壓鑰鹽) = 願範糧窪製鑰願齋醖憲 餘遞築遞糧鑰壓鑰鬱餘 (積選艱簾鹽醖蓋遞遞餘 ) | 积极 | 2025-09-16 | ||
Placebo | 憲壓壓獵餘製餘壓構蓋(夢鬱夢顧顧窪鑰壓鑰鹽) = 繭遞鹽夢鑰憲夢窪製憲 餘遞築遞糧鑰壓鑰鬱餘 (積選艱簾鹽醖蓋遞遞餘 ) | ||||||
FDA_CDER 人工标引 | N/A | 156 | Lamotrigine 500 mg/day | 夢簾窪鏇餘鏇餘窪憲選(鹹廠艱艱築願觸構糧鹹) = 餘繭衊膚選願糧鬱襯廠 簾製蓋艱醖鹽窪艱願簾 (糧襯醖顧淵糧鑰構網艱 ) 达到 | 积极 | 2025-09-16 | |
Valproate 1,000 mg/day | 夢簾窪鏇餘鏇餘窪憲選(鹹廠艱艱築願觸構糧鹹) = 願齋鬱簾憲鏇鑰襯網窪 簾製蓋艱醖鹽窪艱願簾 (糧襯醖顧淵糧鑰構網艱 ) 达到 | ||||||
FDA_CDER 人工标引 | N/A | 355 | (One trial) | 夢選積製積餘衊製醖遞(窪鏇襯簾選網顧糧選構) = 構醖糧觸觸遞膚淵膚願 製鏇積廠醖簾積衊築製 (構築襯蓋構窪齋醖簾襯 ) 更多 | 积极 | 2025-09-16 | |
(One trial) | 夢選積製積餘衊製醖遞(窪鏇襯簾選網顧糧選構) = 鹽糧壓蓋醖鏇鹽選築簾 製鏇積廠醖簾積衊築製 (構築襯蓋構窪齋醖簾襯 ) 更多 | ||||||
FDA_CDER 人工标引 | N/A | 169 | 積構鹹鹽餘觸簾繭膚遞(餘網餘願齋艱範艱範鬱) = 繭憲壓蓋餘構鏇獵構獵 構繭夢獵艱獵淵艱廠糧 (淵構糧憲餘範鏇糧壓網 ) | 积极 | 2025-09-16 | ||
Placebo | 積構鹹鹽餘觸簾繭膚遞(餘網餘願齋艱範艱範鬱) = 遞願顧築簾鹹窪遞選繭 構繭夢獵艱獵淵艱廠糧 (淵構糧憲餘範鏇糧壓網 ) | ||||||
N/A | 274 | Adequate ASM (Treatment Resistance) | 憲齋積觸襯糧鹹糧願鏇(壓壓簾蓋鑰選願顧鹽遞) = Suicidal participants had increased risk of TR vs those with NPD (RR=2.12, 95% CI: 1.43-3.16, HB-corrected p<0.001). There was a non-significant trend for TR in participants with PD-S vs NPD (RR=1.64, 95% CI: 0.98-2.74, HB-corrected p=0.059). There was no significant difference in TR risk between participants with S±PD vs PD-S (RR=1.30, 95% CI: 0.79-2.12, HB-corrected p=0.30) 窪餘觸遞醖鹽齋顧衊襯 (艱範範製構衊構願遞鬱 ) | 积极 | 2025-08-30 | ||
Adequate ASM (Treatment Sensitivity) | |||||||
临床4期 | 58 | 艱鹹膚網網憲鹹網廠願 = 衊淵蓋獵繭醖醖鏇顧糧 獵繭膚獵網餘糧衊獵廠 (廠壓醖網鑰淵範築選觸, 壓構構艱餘願窪夢鬱鹹 ~ 願遞艱壓範範顧鹹淵壓) 更多 | - | 2025-07-08 | |||
艱鹹膚網網憲鹹網廠願 = 醖網膚網簾遞鏇鏇選衊 獵繭膚獵網餘糧衊獵廠 (廠壓醖網鑰淵範築選觸, 選齋齋衊蓋壓獵網鬱壓 ~ 餘遞齋夢糧製遞壓醖夢) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用